Atlas Trials

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

Clinical trial NCT06797531 · RECRUITING

Trial details

NCT number
NCT06797531
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Study type
OBSERVATIONAL
HR+/HER2- Early Breast Cancer
Start date
2025-08-27
Primary completion
2028-11-30
Enrollment
177

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.